Anti-VEGF effects of intravitreal erythropoietin in early diabetic retinopathy

Frontiers in Bioscience - Elite

Volumn 2 E, Issue 3, 2010, Pages 912-927

  Zhang, Jingfa ^a,b   Hu, Liu Mei ^c   Xu, Guoxu ^d   Wu, Yalan ^b   Shen, Jianfeng ^b   Luo, Yan ^c   Zhong, Yong ^c   Sinclair, Stephen H ^e   Yanoff, Myron ^e   Li, Weiye ^a,b,c,e   Xu, Guo Tong ^a,b  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d SOOCHOW UNIVERSITY   (China)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Blood retinal barrier; Diabetic retinopathy; Erythropoietin; Negative feedback; Vascular endothelial growth factor

Indexed keywords

ERYTHROPOIETIN; PRIMER DNA; VASCULOTROPIN A;

ANIMAL; ARTICLE; BLOOD RETINA BARRIER; DIABETIC RETINOPATHY; DRUG ANTAGONISM; ELECTRON MICROSCOPY; MALE; NICK END LABELING; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RAT; SPRAGUE DAWLEY RAT; VITREOUS BODY;

ANIMALS; BASE SEQUENCE; BLOOD-RETINAL BARRIER; DIABETIC RETINOPATHY; DNA PRIMERS; ERYTHROPOIETIN; IN SITU NICK-END LABELING; MALE; MICROSCOPY, ELECTRON; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77957334087     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. J. Bradley, M. Ju and G. S. Robinson: Combination therapy for the treatment of ocular neovascularization. Angiogenesis, 10(2), 141-8 (2007) (Pubitemid 46440632)
2. T. W. Gardner, D. A. Antonetti, A. J. Barber, K. F. LaNoue and S. W. Levison: Diabetic retinopathy: more than meets the eye. Surv Ophthalmol, 47 Suppl 2, S253-62 (2002) (Pubitemid 36351245)
3. E. Lieth, T. W. Gardner, A. J. Barber and D. A. Antonetti: Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol, 28(1), 3-8 (2000) (Pubitemid 30433242)
4. J. Zhang, Y. Wu, Y. Jin, F. Ji, S. H. Sinclair, Y. Luo, G. Xu, L. Lu, W. Dai, M. Yanoff, W. Li and G. T. Xu: Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci, 49(2), 732-42 (2008)
5. E. L. Fletcher, J. A. Phipps, M. M. Ward, T. Puthussery and J. L. Wilkinson-Berka: Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des, 13(26), 2699-712 (2007) (Pubitemid 47423662)
6. A. Sola, T. C. Wen, S. E. Hamrick and D. M. Ferriero: Potential for protection and repair following injury to the developing brain: a role for erythropoietin? Pediatr Res, 57(5 Pt 2), 110R-117R (2005) (Pubitemid 40593255)
7. J. Rossert and K. U. Eckardt: Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant, 20(6), 1025-8 (2005) (Pubitemid 40862086)
8. P. Ghezzi and M. Brines: Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ, 11 Suppl 1, S37-44 (2004) (Pubitemid 39136797)
9. H. Funatsu, H. Yamashita, S. Nakamura, T. Mimura, S. Eguchi, H. Noma and S. Hori: Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology, 113(2), 294-301 (2006) (Pubitemid 43170779)
10. H. Funatsu, H. Yamashita, T. Ikeda, Y. Nakanishi, S. Kitano and S. Hori: Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol, 133(4), 537-43 (2002) (Pubitemid 34258063)
11. T. Murata, T. Ishibashi, A. Khalil, Y. Hata, H. Yoshikawa and H. Inomata: Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res, 27(1), 48-52 (1995)
12. A. N. Witmer, G. F. Vrensen, C. J. Van Noorden and R. O. Schlingemann: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res, 22(1), 1-29 (2003) (Pubitemid 36207453)
13. P. H. Maxwell and P. J. Ratcliffe: Oxygen sensors and angiogenesis. Semin Cell Dev Biol, 13(1), 29-37 (2002) (Pubitemid 35418312)
14. O. Arjamaa and M. Nikinmaa: Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res, 83(3), 473-83 (2006) (Pubitemid 43902768)
15. G. Hopfl, R. H. Wenger, U. Ziegler, T. Stallmach, O. Gardelle, R. Achermann, M. Wergin, B. Kaser-Hotz, H. M. Saunders, K. J. Williams, I. J. Stratford, M. Gassmann and I. Desbaillets: Rescue of hypoxia-inducible factor-1alphadeficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res, 62(10), 2962-70 (2002) (Pubitemid 34525786)
16. J. W. Lee, S. H. Bae, J. W. Jeong, S. H. Kim and K. W. Kim: Hypoxia-inducible factor (HIF-1) alpha: its protein stability and biological functions. Exp Mol Med, 36(1), 1-12 (2004)
17. Q. Ke and M. Costa: Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol, 70(5), 1469-80 (2006)
18. J. H. Yin, D. I. Yang, G. Ku and C. Y. Hsu: iNOS expression inhibits hypoxia-inducible factor-1 activity. Biochem Biophys Res Commun, 279(1), 30-4 (2000)
19. A. J. Barber: A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry, 27(2), 283-90 (2003) (Pubitemid 36351495)
20. A. M. Abu-El-Asrar, L. Dralands, L. Missotten, I. A. Al-Jadaan and K. Geboes: Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis Sci, 45(8), 2760-6 (2004) (Pubitemid 38998875)
21. A. J. Barber, E. Lieth, S. A. Khin, D. A. Antonetti, A. G. Buchanan and T. W. Gardner: Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest, 102(4), 783-91 (1998) (Pubitemid 28399611)
22. P. M. Martin, P. Roon, T. K. Van Ells, V. Ganapathy and S. B. Smith: Death of retinal neurons in streptozotocininduced diabetic mice. Invest Ophthalmol Vis Sci, 45(9), 3330-6 (2004) (Pubitemid 39121873)
23. S. H. Park, J. W. Park, S. J. Park, K. Y. Kim, J. W. Chung, M. H. Chun and S. J. Oh: Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia, 46(9), 1260-8 (2003)
24. A. M. Joussen, V. Poulaki, M. L. Le, K. Koizumi, C. Esser, H. Janicki, U. Schraermeyer, N. Kociok, S. Fauser, B. Kirchhof, T. S. Kern and A. P. Adamis: A central role for inflammation in the pathogenesis of diabetic retinopathy. Faseb J, 18(12), 1450-2 (2004) (Pubitemid 39561611)
25. L. P. Aiello, J. M. Northrup, B. A. Keyt, H. Takagi and M. A. Iwamoto: Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol, 113(12), 1538-44 (1995)
26. A. P. Adamis and D. T. Shima: The role of vascular endothelial growth factor in ocular health and disease. Retina, 25(2), 111-8 (2005) (Pubitemid 40365933)
27. R. B. Caldwell, M. Bartoli, M. A. Behzadian, A. E. El-Remessy, M. Al-Shabrawey, D. H. Platt, G. I. Liou and R. W. Caldwell: Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets, 6(4), 511-24 (2005) (Pubitemid 40916276)
28. H. Funatsu, H. Yamashita, K. Sakata, H. Noma, T. Mimura, M. Suzuki, S. Eguchi and S. Hori: Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology, 112(5), 806-16 (2005) (Pubitemid 40631499)
29. J. Ambati, K. V. Chalam, D. K. Chawla, C. T. D'Angio, E. G. Guillet, S. J. Rose, R. E. Vanderlinde and B. K. Ambati: Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol, 115(9), 1161-6 (1997) (Pubitemid 27387953)
30. T. Murata, K. Nakagawa, A. Khalil, T. Ishibashi, H. Inomata and K. Sueishi: The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest, 74(4), 819-25 (1996) (Pubitemid 26117141)
31. S. Ishida, T. Usui, K. Yamashiro, Y. Kaji, E. Ahmed, K. G. Carrasquillo, S. Amano, T. Hida, Y. Oguchi and A. P. Adamis: VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci, 44(5), 2155-62 (2003)
32. H. Ozaki, H. Hayashi, S. A. Vinores, Y. Moromizato, P. A. Campochiaro and K. Oshima: Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res, 64(4), 505-17 (1997) (Pubitemid 27321334)
33. H. Ahmadieh, A. Ramezani, N. Shoeibi, B. Bijanzadeh, A. Tabatabaei, M. Azarmina, M. Soheilian, G. Keshavarzi and M. R. Mohebbi: Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol, 246(4), 483-9 (2008) (Pubitemid 351447960)
34. S. H. Byeon, Y. A. Kwon, H. S. Oh, M. Kim and O. W. Kwon: Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. J Ocul Pharmacol Ther, 23(4), 387-94 (2007) (Pubitemid 350195064)
35. J. F. Arevalo, J. Fromow-Guerra, H. Quiroz-Mercado, J. G. Sanchez, L. Wu, M. Maia, M. H. Berrocal, A. Solis-Vivanco and M. E. Farah: Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology, 114(4), 743-50 (2007) (Pubitemid 46483714)
36. E. T. Cunningham, Jr., A. P. Adamis, M. Altaweel, L. P. Aiello, N. M. Bressler, D. J. D'Amico, M. Goldbaum, D. R. Guyer, B. Katz, M. Patel and S. D. Schwartz: A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology, 112(10), 1747-57 (2005) (Pubitemid 41400011)
37. J. F. Zhang, Y. L. Wu, J. Y. Xu, W. Ye, Y. Zhang, H. Weng, W. D. Shi, G. X. Xu, L. Lu, W. Dai, S. H. Sinclair, W. Y. Li and G. T. Xu: Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits. Acta Pharmacol Sin, 29(11), 1383-90 (2008)
38. O. M. Martinez-Estrada, E. Rodriguez-Millan, E. Gonzalez-De Vicente, M. Reina, S. Vilaro and M. Fabre: Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci, 18(9), 2538-44 (2003) (Pubitemid 37452669)
39. Y. Li, M. E. Ogle, G. C. t. Wallace, Z. Y. Lu, S. P. Yu and L. Wei: Erythropoietin attenuates intracerebral hemorrhage by diminishing matrix metalloproteinases and maintaining blood-brain barrier integrity in mice. Acta Neurochir Suppl, 105, 105-12 (2008)
40. Y. Li, Z. Y. Lu, M. Ogle and L. Wei: Erythropoietin prevents blood brain barrier damage induced by focal cerebral ischemia in mice. Neurochem Res, 32(12), 2132-41 (2007) (Pubitemid 350059857)
41. G. Chen, J. X. Shi, C. H. Hang, W. Xie, J. Liu and X. Liu: Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci Lett, 425(3), 177-82 (2007) (Pubitemid 47418362)
42. O. Z. Chi, C. Hunter, X. Liu and H. R. Weiss: Effects of erythropoietin on blood-brain barrier disruption in focal cerebral ischemia. Pharmacology, 82(1), 38-42 (2008) (Pubitemid 351931408)
43. D. Watanabe, K. Suzuma, S. Matsui, M. Kurimoto, J. Kiryu, M. Kita, I. Suzuma, H. Ohashi, T. Ojima, T. Murakami, T. Kobayashi, S. Masuda, M. Nagao, N. Yoshimura and H. Takagi: Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med, 353(8), 782-92 (2005) (Pubitemid 41215487)
44. X. B. Liu, J. A. Wang, S. P. Yu, C. L. Keogh and L. Wei: Therapeutic strategy of erythropoietin in neurological disorders. CNS Neurol Disord Drug Targets, 7(3), 227-34 (2008)
45. K. Gora-Kupilas and J. Josko: The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol, 43(1), 31-9 (2005) (Pubitemid 40533190)
46. C. Hernandez, A. Fonollosa, M. Garcia-Ramirez, M. Higuera, R. Catalan, A. Miralles, J. Garcia-Arumi and R. Simo: Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care, 29(9), 2028-33 (2006) (Pubitemid 44871182)
47. A. M. Abu El-Asrar, L. Missotten and K. Geboes: Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol, 91(6), 822-6 (2007) (Pubitemid 46846660)
48. B. Brune, J. Zhou and A. von Knethen: Nitric oxide, oxidative stress, and apoptosis. Kidney Int Suppl (84), S22-4 (2003)
49. K. H. Moley and M. M. Mueckler: Glucose transport and apoptosis. Apoptosis, 5(2), 99-105 (2000) (Pubitemid 30399383)
50. F. Forooghian, R. Razavi and L. Timms: Hypoxiainducible factor expression in human RPE cells. Br J Ophthalmol, 91(10), 1406-10 (2007) (Pubitemid 47492884)
51. Y. Katsura, T. Okano, K. Matsuno, M. Osako, M. Kure, T. Watanabe, Y. Iwaki, M. Noritake, H. Kosano, H. Nishigori and T. Matsuoka: Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Care, 28(9), 2252-4 (2005) (Pubitemid 41242480)
52. D. A. Gewirtz, X. Di, T. D. Walker and S. T. Sawyer: Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin Cancer Res, 12(7 Pt 1), 2232-8 (2006)
53. W. Li, S. H. Sinclair and G.-T. Xu: Effects of Intravitreal Erythropoietin Therapy for Patients with Chronic and Progressive Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging, [in press] (2009)
54. H. Diez, A. Fischer, A. Winkler, C. J. Hu, A. K. Hatzopoulos, G. Breier and M. Gessler: Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp Cell Res, 313(1), 1-9 (2007) (Pubitemid 44958449)
55. S. A. Hale, C. Wong and K. M. Lounsbury: Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells. Gynecol Oncol, 100(1), 14-9 (2006) (Pubitemid 41815043)
56. K. K. To and L. E. Huang: Suppression of hypoxiainducible factor 1alpha (HIF-1alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1. J Biol Chem, 280(45), 38102-7 (2005) (Pubitemid 41642425)
57. J. Karhausen, T. Kong, S. Narravula and S. P. Colgan: Induction of the von Hippel-Lindau tumor suppressor gene by late hypoxia limits HIF-1 expression. J Cell Biochem, 95(6), 1264-75 (2005) (Pubitemid 41420132)